Advances on non-CD4 + Foxp3+ T regulatory cells: CD8+, type 1, and double negative T regulatory cells in organ transplantation

Transplantation

Volumn 99, Issue 8, 2015, Pages 1553-1559

  Ligocki, Ann J ^a   Niederkorn, Jerry Y ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD103 ANTIGEN; CD28 ANTIGEN; CD30 ANTIGEN; CD4 ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FAS LIGAND; FINGOLIMOD; GAMMA INTERFERON; GLYCOPROTEIN P 15095; HISTONE DEACETYLASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN; RAPAMYCIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA2; TRICHOSTATIN A; BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT;

ALLOGRAFT; ANTIGEN PRESENTING CELL; APOPTOSIS; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POPULATION; CYTOLYSIS; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; NATURAL KILLER CELL; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH17 CELL; TH2 CELL; XENOGRAFT; ADVERSE EFFECTS; ANIMAL; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; PHENOTYPE; SIGNAL TRANSDUCTION; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME;

ANIMALS; BIOMARKERS; CD8-POSITIVE T-LYMPHOCYTES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; PHENOTYPE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME;

EID: 84942437002     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000813     Document Type: Review

References (99)

1. Gershon RK, Cohen P, Hencin R, et al. Suppressor T cells. J Immunol. 1972;108(3):586-590.
2. Moller G. Do suppressor T cells exist? Scand J Immunol. 1988;27(3): 247-250.
3. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155(3):1151-1164.
4. Cantor H, Shen FW, Boyse EA. Separation of helper T cells from suppressor T cells expressing different Ly components. II. Activation by antigen: after immunization, antigen-specific suppressor and helper activities are mediated by distinct T-cell subclasses. J Exp Med. 1976;143(6):1391-40.
5. Hu D, Ikizawa K, Lu L, et al. Analysis of regulatory CD8 T cells in Qa-1-deficient mice. Nat Immunol. 2004;5(5):516-523.
6. Jiang H, Chess L. Qa-1/HLA-E-restricted regulatory CD8+ Tcells and selfnonself discrimination: an essay on peripheral T-cell regulation. Hum Immunol. 2008;69(11):721-727.
7. Kim HJ, Cantor H. Regulation of self-tolerance by Qa-1-restricted CD8(+) regulatory T cells. Semin Immunol. 2011;23(6):446-452.
8. Rifa'i M, Kawamoto Y, Nakashima I, et al. Essential roles of CD8 + CD122 + regulatory T cells in the maintenance of T cell homeostasis. J ExpMed. 2004;200(9):1123-1134.
9. Strioga M, Pasukoniene V, Characiejus D. CD8+ CD28- and CD8+ CD57+ Tcells and their role in health and disease. Immunology. 2011;134(1):17-32.
10. Mahic M, Henjum K, Yaqub S, et al. Generation of highly suppressive adaptive CD8(+)CD25(+)FOXP3(+) regulatory T cells by continuous antigen stimulation. Eur J Immunol. 2008;38(3):640-646.
11. Uss E, Rowshani AT, Hooibrink B, et al. CD103 is amarker for alloantigeninduced regulatory CD8+ T cells. J Immunol. 2006;177(5):2775-2783.
12. Boor PP, Metselaar HJ, Jonge S, et al. Human plasmacytoid dendritic cells induce CD8(+) LAG-3(+) Foxp3(+) CTLA-4(+) regulatory T cells that suppress allo-reactive memory T cells. Eur J Immunol. 2011;41(6): 1663-1674.
13. Wei S, Kryczek I, Zou L, et al. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res. 2005;65 (12):5020-5026.
14. Xystrakis E, Dejean AS, Bernard I, et al. Identification of a novel natural regulatory CD8 T-cell subset and analysis of its mechanism of regulation. Blood. 2004;104(10):3294-3301.
15. Dai H, Wan N, Zhang S, et al. Cutting edge: programmed death-1 defines CD8 + CD122+ T cells as regulatory versus memory T cells. J Immunol. 2010;185(2):803-807.
16. Chen Z, Han Y, Gu Y, et al. CD11c(high)CD8+ regulatory T cell feedback inhibits CD4 T cell immune response via Fas ligand-Fas pathway. J Immunol. 2013;190(12):6145-6154.
17. Zhang ZX, Yang L, Young KJ, et al. Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression. Nat Med. 2000;6(7):782-789.
18. Zhang D, Yang W, Degauque N, et al. New differentiation pathway for double-negative regulatory T cells that regulates the magnitude of immune responses. Blood. 2007;109(9):4071-4079.
19. Fischer K, Voelkl S, Heymann J, et al. Isolation and characterization of human antigen-specific TCR alpha beta + CD4(-)CD8-double-negative regulatory T cells. Blood. 2005;105(7):2828-2835.
20. Gagliani N, Magnani CF, Huber S, et al. Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med. 2013;19(6):739-746.
21. Liu J, Liu Z, Witkowski P, et al. Rat CD8+ FOXP3+ T suppressor cells mediate tolerance to allogeneic heart transplants, inducing PIR-B in APC and rendering the graft invulnerable to rejection. Transpl Immunol. 2004;13(4):239-247.
22. Streilein JW, Niederkorn JY. Characterization of the suppressor cell (s) responsible for anterior chamber-associated immune deviation (ACAID) induced in BALB/c mice by P815 cells. J Immunol. 1985;134(3): 1381-1387.
23. Picarda E, Bezie S, Venturi V, et al. MHC-derived allopeptide activates TCR-biased CD8+ Tregs and suppresses organ rejection. J Clin Invest. 2014;124(6):2497-2512.
24. Wang J, Jiang S, Shi H, et al. Prolongation of corneal xenotransplant survival by T-cell vaccination-induced T-regulatory cells. Xenotransplantation. 2008;15(3):164-173.
25. Guillonneau C, Hill M, Hubert FX, et al. CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase. J Clin Invest. 2007;117(4):1096-1106.
26. Li S, Xie Q, Zeng Y, et al. A naturally occurring CD8(+)CD122(+) T-cell subset as a memory-like Treg family. Cell Mol Immunol. 2014;11(4): 326-331.
27. Barbon CM, Davies JK, Voskertchian A, et al. Alloanergization of human T cells results in expansion of alloantigen-specific CD8(+) CD28(-) suppressor cells. Am J Transplant. 2014;14(2):305-318.
28. Li XL, Menoret S, Bezie S, et al. Mechanism and localization of CD8 regulatory T cells in a heart transplant model of tolerance. J Immunol. 2010;185(2):823-833.
29. Lu L, Cantor H. Generation and regulation of CD8(+) regulatory Tcells. Cell Mol Immunol. 2008;5(6):401-406.
30. Lu L, Kim HJ, Werneck MB, et al. Regulation of CD8+ regulatory T cells: interruption of the NKG2A-Qa-1 interaction allows robust suppressive activity and resolution of autoimmune disease. Proc Natl Acad Sci U S A. 2008;105(49):19420-19425.
31. Lerret NM, Houlihan JL, Kheradmand T, et al. Donor-specific CD8+ Foxp3+ T cells protect skin allografts and facilitate induction of conventional CD4+ Foxp3+ regulatory T cells. Am J Transplant. 2012;12(9):2335-2347.
32. Endharti AT, Rifa IM, Shi Z, et al. Cutting edge: CD8 + CD122+ regulatory T cells produce IL-10 to suppress IFN-gamma production and proliferation of CD8+ T cells. J Immunol. 2005;175(11):7093-7097.
33. Mangalam AK, Luckey D, Giri S, et al. Two discreet subsets of CD8 T cells modulate PLP(91-110) induced experimental autoimmune encephalomyelitis in HLA-DR3 transgenic mice. J Autoimmun. 2012;38(4):344-353.
34. Gaur A, Ruberti G, Haspel R, et al. Requirement for CD8+ cells in T cell receptor peptide-induced clonal unresponsiveness. Science. 1993;259 (5091):91-94.
35. Koh DR, Fung-Leung WP, Ho A, et al. Less mortality but more relapses in experimental allergic encephalomyelitis in CD8-/- mice. Science. 1992; 256(5060):1210-1213.
36. Varthaman A, Khallou-Laschet J, Clement M, et al. Control of T cell reactivation by regulatory Qa-1-restricted CD8+ T cells. J Immunol. 2010;184(12):6585-6591.
37. Cone RE, Chattopadhyay S, Sharafieh R, et al. The suppression of hypersensitivity by ocular-induced CD8(+) T cells requires compatibility in the Qa-1 haplotype. Immunol Cell Biol. 2009;87(3):241-248.
38. D'Orazio TJ, Mayhew E, Niederkorn JY. Ocular immune privilege promoted by the presentation of peptide on tolerogenic B cells in the spleen. II. Evidence for presentation by Qa-1. J Immunol. 2001;166 (1):26-32.
39. Dai Z, Zhang S, Xie Q, et al. Natural CD8 + CD122+ Tcells aremore potent in suppression of allograft rejection than CD4 + CD25+ regulatory T cells. Am J Transplant. 2014;14(1):39-48.
40. Guillonneau C, Picarda E, Anegon I. CD8+ regulatory Tcells in solid organ transplantation. Curr Opin Organ Transplant. 2010;15(6):751-756.
41. Wan N, Dai H, Wang T, et al. Bystander central memory but not effector memory CD8+ T cells suppress allograft rejection. J Immunol. 2008;180 (1):113-121.
42. Sireci G, Barera A, Macaluso P, et al. A continuous infusion of a minor histocompatibility antigen-immunodominant peptide induces a delay of male skin graft rejection. Immunobiology. 2009;214(8):703-711.
43. Ford MS, Young KJ, Zhang Z, et al. The immune regulatory function of lymphoproliferative double negative T cells in vitro and in vivo. J Exp Med. 2002;196(2):261-267.
44. Colovai AI, Mirza M, Vlad G, et al. Regulatory CD8 + CD28-Tcells in heart transplant recipients. Hum Immunol. 2003;64(1):31-37.
45. Kapp JA, Honjo K, Kapp LM, et al. TCR transgenic CD8+ Tcells activated in the presence of TGFbeta express FoxP3 andmediate linked suppression of primary immune responses and cardiac allograft rejection. Int Immunol. 2006;18(11):1549-1562.
46. Zhang ZX, Lian D, Huang X, et al. Adoptive transfer of DNTcells induces long-term cardiac allograft survival and augments recipient CD4(+)Foxp3 (+) Treg cell accumulation. Transpl Immunol. 2011;24(2):119-126.
47. Chen W, Ford MS, Young KJ, et al. Infusion of in vitro-generated DN T regulatory cells induces permanent cardiac allograft survival in mice. Transplant Proc. 2003;35(7):2479-2480.
48. Hill M, Thebault P, Segovia M, et al. Cell therapy with autologous tolerogenic dendritic cells induces allograft tolerance through interferongamma and epstein-barr virus-induced gene 3. Am J Transplant. 2011;11(10):2036-2045.
49. Zhang D, Zhang W, Ng TW, et al. Adoptive cell therapy using antigenspecific CD4(-)CD8(-)T regulatory cells to prevent autoimmune diabetes and promote islet allograft survival in NOD mice. Diabetologia. 2011;54 (8):2082-2092.
50. Battaglia M, Stabilini A, Draghici E, et al. Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. Diabetes. 2006;55(1):40-49.
51. Gagliani N, Jofra T, Stabilini A, et al. Antigen-specific dependence of Tr1-cell therapy in preclinical models of islet transplant. Diabetes. 2010;59 (2):433-439.
52. Huurman VA, Velthuis JH, Hilbrands R, et al. Allograft-specific cytokine profiles associate with clinical outcome after islet cell transplantation. Am J Transplant. 2009;9(2):382-388.
53. Zhou J, Appleton SE, Stadnyk A, et al. CD8+ gammadelta T regulatory cells mediate kidney allograft prolongation after oral exposure to alloantigen. Transpl Int. 2008;21(7):679-687.
54. VanBuskirk AM, Burlingham WJ, Jankowska-Gan E, et al. Human allograft acceptance is associated with immune regulation. J Clin Invest. 2000;106(1):145-155.
55. Ma Y, He KM, Garcia B, et al. Adoptive transfer of double negative T regulatory cells induces B-cell death in vivo and alters rejection pattern of rat-to-mouse heart transplantation. Xenotransplantation. 2008;15 (1):56-63.
56. Chen W, Ford MS, Young KJ, et al. Role of double-negative regulatory T cells in long-term cardiac xenograft survival. J Immunol. 2003;170 (4):1846-1853.
57. Beres AJ, Haribhai D, Chadwick AC, et al. CD8+ Foxp3+ regulatory Tcells are induced during graft-versus-host disease and mitigate disease severity. J Immunol. 2012;189(1):464-474.
58. He KM, Ma Y, Wang S, et al. Donor double-negative Treg promote allogeneic mixed chimerism and tolerance. Eur J Immunol. 2007;37(12): 3455-3466.
59. McIver Z, Serio B, Dunbar A, et al. Double-negative regulatory T cells induce allotolerance when expanded after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2008;141(2):170-178.
60. Serafini G, Andreani M, Testi M, et al. Type 1 regulatory T cells are associated with persistent split erythroid/lymphoid chimerism after allogeneic hematopoietic stem cell transplantation for thalassemia. Haematologica. 2009;94(10):1415-1426.
61. Niederkorn JY. See no evil, hear no evil, do no evil: the lessons of immune privilege. Nat Immunol. 2006;7(4):354-359.
62. Cone RE, Li X, Sharafieh R, et al. The suppression of delayed-type hypersensitivity by CD8+ regulatory T cells requires interferon-gamma. Immunology. 2007;120(1):112-119.
63. Yamada Y, Sugita S, Horie S, et al. Mechanisms of immune suppression for CD8+ T cells by human corneal endothelial cells via membranebound TGFbeta. Invest Ophthalmol Vis Sci. 2010;51(5):2548-2557.
64. Sugita S, Keino H, Futagami Y, et al. B7+ iris pigment epithelial cells convert T cells into CTLA-4+, B7-expressing CD8+ regulatory T cells. Invest Ophthalmol Vis Sci. 2006;47(12):5376-5384.
65. Sugita S, Ng TF, Lucas PJ, et al. B7+ iris pigment epithelium induce CD8+ T regulatory cells; both suppress CTLA-4+ T cells. J Immunol. 2006;176 (1):118-127.
66. Niederkorn JY. Anterior chamber-associated immune deviation and its impact on corneal allograft survival. Curr Opin Organ Transplant. 2006;11:360-365.
67. Niederkorn JY, Mellon J. Anterior chamber-associated immune deviation promotes corneal allograft survival. Invest Ophthalmol Vis Sci. 1996;37 (13):2700-2707.
68. Strober S, Dejbachsh-Jones S, Van Vlasselaer P, et al. Cloned natural suppressor cell lines express the CD3 + CD4-CD8-surface phenotype and the alpha, beta heterodimer of the T cell antigen receptor. J Immunol. 1989;143(4):1118-1122.
69. Zhang ZX, Young K, Zhang L. CD3 + CD4-CD8-alphabeta-TCR+ Tcell as immune regulatory cell. J Mol Med. 2001;79(8):419-427.
70. Juvet SC, Zhang L. Double negative regulatory T cells in transplantation and autoimmunity: recent progress and future directions. J Mol Cell Biol. 2012;4(1):48-58. PubMed PMID: 22294241.
71. Balomenos D, Rumold R, Theofilopoulos AN. The proliferative in vivo activities of lpr double-negative T cells and the primary role of p59fyn in their activation and expansion. J Immunol. 1997;159(5):2265-2273.
72. Gao JF, McIntyre MS, Juvet SC, et al. Regulation of antigen-expressing dendritic cells by double negative regulatory T cells. Eur J Immunol. 2011;41(9):2699-2708.
73. Ford McIntyre MS, Young KJ, Gao J, et al. Cutting edge: in vivo trogocytosis as a mechanism of double negative regulatory T cell-mediated antigenspecific suppression. J Immunol. 2008;181(4):2271-2275.
74. Thomson CW, Lee BP, Zhang L. Double-negative regulatory T cells: nonconventional regulators. Immunol Res. 2006;35(1-2):163-178.
75. Young KJ, Zhang L. The nature and mechanisms of DN regulatory T-cell mediated suppression. Hum Immunol. 2002;63(10):926-934.
76. Miller RG. An immunological suppressor cell inactivating cytotoxic T-lymphocyte precursor cells recognizing it. Nature. 1980;287(5782):544-546.
77. Voelkl S, Gary R, Mackensen A. Characterization of the immunoregulatory function of human TCR-alphabeta + CD4-CD8-double-negative T cells. Eur J Immunol. 2011;41(3):739-748.
78. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(5609):1057-1061.
79. Groux H, O'Garra A, Bigler M, et al. A CD4+ T-cell subset inhibits antigenspecific T-cell responses and prevents colitis. Nature. 1997;389(6652): 737-742.
80. Roncarolo MG, Gregori S, Battaglia M, et al. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev. 2006; 212:28-50.
81. Volchenkov R, Karlsen M, Jonsson R, et al. Type 1 regulatory T cells and regulatory B cells induced by tolerogenic dendritic cells. Scand J Immunol. 2013;77(4):246-254.
82. Awasthi A, Carrier Y, Peron JP, et al. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol. 2007;8(12):1380-1389.
83. Fitzgerald DC, Zhang GX, El-Behi M, et al. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat Immunol. 2007;8(12):1372-1379.
84. Stumhofer JS, Silver JS, Laurence A, et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol. 2007; 8(12):1363-1371.
85. Murugaiyan G, Mittal A, Lopez-Diego R, et al. IL-27 is a key regulator of IL-10 and IL-17 production by human CD4+ T cells. J Immunol. 2009; 183(4):2435-2443.
86. Jin JO, Han X, Yu Q. Interleukin-6 induces the generation of IL-10-producing Tr1 cells and suppresses autoimmune tissue inflammation. J Autoimmun. 2013;40:28-44.
87. Magnani CF, Alberigo G, Bacchetta R, et al. Killing of myeloid APCs via HLA class I, CD2 and CD226 defines a novel mechanism of suppression by human Tr1 cells. Eur J Immunol. 2011;41(6):1652-1662.
88. Huber S, Gagliani N, Esplugues E, et al. Th17 cells express interleukin-10 receptor and are controlled by Foxp3(-) and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. Immunity. 2011;34(4): 554-565.
89. Bacchetta R, Bigler M, Touraine JL, et al. High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J Exp Med. 1994;179(2):493-502.
90. Coenen JJ, Koenen HJ, van Rijssen E, et al. Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells. Bone Marrow Transplant. 2007;39(9):537-545.
91. Gao W, Lu Y, El Essawy B, et al. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant. 2007;7(7):1722-1732.
92. Lim DG, Koo SK, Park YH, et al. Impact of immunosuppressants on the therapeutic efficacy of in vitro-expanded CD4 + CD25 + Foxp3+ regulatory T cells in allotransplantation. Transplantation. 2010;89 (8):928-936.
93. Liu Y, Jiang J, Xiao H, et al. Topical application of FTY720 and cyclosporin A prolong corneal graft survival in mice. Mol Vis. 2012; 18:624-633.
94. Wu T, Zhang L, Xu K, et al. Immunosuppressive drugs on inducing Agspecific CD4(+)CD25(+)Foxp3(+) Treg cells during immune response in vivo. Transpl Immunol. 2012;27(1):30-38.
95. Zhang X, Han S, Kang Y, et al. SAHA, an HDAC inhibitor, synergizes with tacrolimus to prevent murine cardiac allograft rejection. Cell Mol Immunol. 2012;9(5):390-398.
96. Sugimoto K, Itoh T, Takita M, et al. Improving allogeneic islet transplantation by suppressing Th17 and enhancing Treg with histone deacetylase inhibitors. Transpl Int. 2014;27(4):408-415.
97. Mao R, Xiao W, Liu H, et al. Systematic evaluation of 640 FDA drugs for their effect on CD4(+)Foxp3(+) regulatory T cells using a novel cell-based high throughput screening assay. Biochem Pharmacol. 2013;85(10): 1513-1524.
98. Uss E, Yong SL, Hooibrink B, et al. Rapamycin enhances the number of alloantigen-induced human CD103 + CD8+ regulatory T cells in vitro. Transplantation. 2007;83(8):1098-1106.
99. Ceeraz S, Hall C, Choy EH, et al. Defective CD8 + CD28+ regulatory Tcell suppressor function in rheumatoid arthritis is restored by tumour necrosis factor inhibitor therapy. Clin Exp Immunol. 2013;174(1):18-26.